Patient characteristics
| Pt no. . | Age, y . | Sex . | CML phase . | Sokal score . | Previous therapy . | IFN duration, mo . | Best response to IFN . | Last response at start of IM . | IM treatment duration for undetectable BCR-ABL transcripts, mo . | IM treatment duration with a negative RTQ-PCR, mo . | Reappearance of BCR-ABL transcripts (level, %*) . | Duration of undetectable BCR-ABL transcripts, mo . | IM treatment duration after molecular relapse, mo/last RTQ-PCR result, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42 | F | CP | L | IM + Ara-C | 0 | — | No Resp | 10 | 26 | Yes (0.02) | 3 | 7/undetec |
| 2 | 54 | M | CP | L | IM + Ara-C | 0 | — | No Resp | 17 | 30 | Yes (0.3) | 2 | 4/0.015 |
| 3 | 75 | F | CP | H | HU + IFN | 9 | No Resp | No Resp | 11 | 45 | Yes (0.015) | 1 | 9/0.001 |
| 4 | 83 | F | CP | I | HU + IFN | 29 | No Resp | No Resp | 11 | 45 | Yes (0.01) | 2 | 6/0.002 |
| 5 | 73 | M | AP | — | IFN | 63 | mCR | mCR | 14 | 42 | Yes (0.002) | 1 | 8/undetec |
| 6 | 58 | F | CP | L | IFN | 71 | CCR | No Resp | 5 | 27 | Yes (0.03) | 5 | 1/0.03 |
| 7 | 76 | M | CP | I | IFN + Ara-C | 29 | mCR | No Resp | 14 | 32 | No | 22† | — |
| 8 | 68 | M | CP | I | IFN | 29 | CCR | No Resp | 4 | 44 | No | 9† | — |
| 9 | 58 | F | CP | I | IFN + Ara-C and AHSCT | 32 | mCR | No Resp | 16 | 24 | No | 24† | — |
| 10 | 71 | M | CP | L | HU + IFN and AHSCT | 33 | CCR | PCgR | 11 | 34 | No | 21† | — |
| 11 | 66 | F | CP | L | IFN | 67 | CCR | PCgR | 5 | 32 | No | 15† | — |
| 12 | 78 | M | CP | I | IFN | 152 | CCR | No Resp | 6 | 32 | No | 9† | — |
| Pt no. . | Age, y . | Sex . | CML phase . | Sokal score . | Previous therapy . | IFN duration, mo . | Best response to IFN . | Last response at start of IM . | IM treatment duration for undetectable BCR-ABL transcripts, mo . | IM treatment duration with a negative RTQ-PCR, mo . | Reappearance of BCR-ABL transcripts (level, %*) . | Duration of undetectable BCR-ABL transcripts, mo . | IM treatment duration after molecular relapse, mo/last RTQ-PCR result, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42 | F | CP | L | IM + Ara-C | 0 | — | No Resp | 10 | 26 | Yes (0.02) | 3 | 7/undetec |
| 2 | 54 | M | CP | L | IM + Ara-C | 0 | — | No Resp | 17 | 30 | Yes (0.3) | 2 | 4/0.015 |
| 3 | 75 | F | CP | H | HU + IFN | 9 | No Resp | No Resp | 11 | 45 | Yes (0.015) | 1 | 9/0.001 |
| 4 | 83 | F | CP | I | HU + IFN | 29 | No Resp | No Resp | 11 | 45 | Yes (0.01) | 2 | 6/0.002 |
| 5 | 73 | M | AP | — | IFN | 63 | mCR | mCR | 14 | 42 | Yes (0.002) | 1 | 8/undetec |
| 6 | 58 | F | CP | L | IFN | 71 | CCR | No Resp | 5 | 27 | Yes (0.03) | 5 | 1/0.03 |
| 7 | 76 | M | CP | I | IFN + Ara-C | 29 | mCR | No Resp | 14 | 32 | No | 22† | — |
| 8 | 68 | M | CP | I | IFN | 29 | CCR | No Resp | 4 | 44 | No | 9† | — |
| 9 | 58 | F | CP | I | IFN + Ara-C and AHSCT | 32 | mCR | No Resp | 16 | 24 | No | 24† | — |
| 10 | 71 | M | CP | L | HU + IFN and AHSCT | 33 | CCR | PCgR | 11 | 34 | No | 21† | — |
| 11 | 66 | F | CP | L | IFN | 67 | CCR | PCgR | 5 | 32 | No | 15† | — |
| 12 | 78 | M | CP | I | IFN | 152 | CCR | No Resp | 6 | 32 | No | 9† | — |
Pt indicates patient; CML, chronic myelogenous leukemia; IFN, recombinant interferon alpha; IM, imatinib mesylate; CP, chronic-phase CML; L, low Sokal score; Ara-C, cytarabine; —, not applicable; No Resp, absence of cytogenetic response; undetec, undetectable BCR-ABL transcript; H, high Sokal score; HU, hydroxyurea; I, intermediate Sokal score; AP, accelerated-phase CML; mCR, minor cytogenetic response; CCR, complete cytogenetic response; AHSCT, autologous hematopoietic stem cell transplantation; PCgR, partial cytogenetic response.
Normalized level of BCR-ABL/ABL ratio.
Last follow-up with undetectable BCR-ABL transcript.